Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction. The investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure.
Heart failure (HF) is a major cause of morbidity and mortality world wide. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and has direct effects on the cardiovascular system. In our previous study, the GLP-1 analogue liraglutide could improve left ventricular function in patients with non-ST-segment elevation myocardial infarction. However, the effects of GLP-1 on HF patients remain unclear. Pulse indicator continuous cardiac output (PiCCO) technology is a combination of transpulmonary thermodilution and pulse contour analysis, which measures hemodynamic variables (left ventricular ejection fraction, volumes, and mass) in a fast and feasible way. Therefore, the aim of this study was to evaluate the effects of liraglutide on hemodynamic variables in HF patients using the PiCCO system.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
Liraglutide were taken daily for 7 days
Placebo were taken daily for 7 days
PLA General Hospital
Beijing, Beijing Municipality, China
RECRUITINGa change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology
The primary efficacy endpoint was the effect of liraglutide on cardiac output (CO) at 7 days compared with placebo.
Time frame: 7 days after treatment
a change in left ventricular contractile index measured by PiCCO technology
The change in left ventricular contractile index was measured at 7 days after treatment.
Time frame: 7 days after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.